If you developed tardive dyskinesia after taking Reglan (metoclopramide), you may be eligible to file a lawsuit in Washington. The FDA requires a black box warning about this risk, especially with long-term use. Consult a qualified attorney to discuss your case and legal options.
If you or a loved one has taken Reglan (metoclopramide) and developed involuntary muscle movements, you may be concerned about tardive dyskinesia. This condition can persist even after stopping the medication. Building on decades of pharmacovigilance research, this page explains who is at higher risk and why monitoring is essential for early detection.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent prescribed for conditions such as diabetic gastroparesis and gastroesophageal reflux. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. This section examines the clinical presentation, pharmacological mechanisms, and risk considerations for patients in Washington who may be affected. Tardive dyskinesia is characterized by involuntary, repetitive movements, often involving the face, tongue, or extremities. These movements can be disfiguring and may include lip smacking, grimacing, or rapid jerking of the limbs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Diagnosis relies on clinical observation, as there is no definitive laboratory test. The condition can be suppressed or masked by continued use of metoclopramide, potentially delaying recognition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). A case report highlights that TD can occur even after a single dose of metoclopramide, particularly in patients with underlying risk factors (https://pubmed.ncbi.nlm.nih.gov/34712535/). This underscores the importance of prompt evaluation when symptoms emerge.
Reglan (metoclopramide) acts by blocking dopamine D2 receptors in the brain, which can lead to extrapyramidal side effects, including TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). The FDA-approved labeling includes a boxed warning stating that metoclopramide can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, treatment should not exceed 12 weeks; for symptomatic gastroesophageal reflux, the maximum duration is also 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling advises using Reglan for the shortest time necessary and periodically reassessing the need for continued therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs of TD develop, immediate discontinuation is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The primary mechanism involves chronic dopamine D2 receptor blockade, which can lead to receptor supersensitivity and altered neurotransmission in the basal ganglia, resulting in involuntary movements (https://pubmed.ncbi.nlm.nih.gov/34712535/). This pathway explains why prolonged exposure increases risk. Additionally, metoclopramide may suppress early signs of TD, complicating diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition can be irreversible, emphasizing the need for careful monitoring.
The FDA has mandated a boxed warning on Reglan labeling, which clearly states the risk of TD and the importance of short-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, medicolegal analyses suggest that both physicians and pharmaceutical companies may face liability if warnings are inadequate or not communicated effectively (https://pubmed.ncbi.nlm.nih.gov/31356297/). In Washington, patients who developed TD after Reglan use may have legal recourse if they were not adequately informed of the risks. The boxed warning is a strong regulatory measure, but its effectiveness depends on prescriber adherence and patient education.
For patients in Washington who have developed TD after Reglan use, settlement considerations often involve the timeline between exposure and harm, the severity of symptoms, and whether warnings were heeded. The risk of TD increases with cumulative exposure, but cases have been reported after short-term use (https://pubmed.ncbi.nlm.nih.gov/34712535/). Legal claims may focus on failure to warn, as the boxed warning exists but may not have been communicated to patients (https://pubmed.ncbi.nlm.nih.gov/31356297/). Affected individuals should document their treatment history, including duration and dosage, and seek legal counsel to evaluate potential claims. The onset of TD can vary widely. While chronic use over months or years is a common risk factor, a case report describes TD after a single intraoperative dose of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). This variability complicates prediction and underscores the need for vigilance. The FDA labeling advises immediate discontinuation if symptoms appear, but the condition may persist or become permanent (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients should monitor for any abnormal movements during or after Reglan therapy and report them promptly.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used for gastrointestinal conditions. It can cause tardive dyskinesia, a potentially irreversible movement disorder, due to chronic dopamine receptor blockade leading to receptor supersensitivity. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Symptoms include involuntary, repetitive movements such as lip smacking, grimacing, tongue protrusion, and rapid jerking of the limbs. Diagnosis is clinical, as there is no definitive lab test (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The onset varies widely. While chronic use over months or years increases risk, cases have been reported after a single dose (https://pubmed.ncbi.nlm.nih.gov/34712535/). The FDA recommends using Reglan for the shortest duration necessary, not exceeding 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Tardive dyskinesia can be irreversible, even after discontinuation of Reglan. Immediate discontinuation is recommended if symptoms appear, but the condition may persist (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Patients may have claims for failure to warn, as the boxed warning exists but may not have been communicated effectively. Consulting an attorney experienced in pharmaceutical liability is advisable (https://pubmed.ncbi.nlm.nih.gov/31356297/).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.